BioSpace News Archive

Extendicare Inc. reported results for the three months ended March 31, 2022.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three months ended March 31, 2022.

Novanta Inc. announced that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird’s 2022 Global Consumer, Technology & Services Conference on Tuesday, June 7, 2022, in New York, NY.

Fulcrum Therapeutics, Inc® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will be presenting two posters at the European Hematology Association (EHA) Hybrid Congress which will take place June 9-12, 2022, in Vienna, Austria.

The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31, 2022.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D. will become an executive director at the prestigious University of Colorado Gates Institute.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, provides a business update and reports financial results for the quarter ended March 31, 2022.

DICE Therapeutics, Inc. reported financial results and business highlights for the first quarter ended March 31, 2022.

Imago BioSciences, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.